Company news
Palvella Therapeutics, Inc. news in 2022
Palvella Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference
November 22, 2022
Pieris Pharmaceuticals to Present at Jefferies London Healthcare Conference
November 8, 2022
Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220
October 31, 2022
Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 7, 2022
Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS
August 23, 2022
Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022
July 27, 2022
Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference
June 1, 2022
Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference
May 17, 2022
Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 10, 2022
Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022
May 3, 2022
Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022
February 22, 2022
Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 4–1BB/HER2 Bispecific Cinrebafusp Alfa
January 13, 2022
Pieris Pharmaceuticals Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402
January 2, 2022